NAD+ and Pinealon Interaction: Compatible | Peptide Database

Join others researching GHRP-2 — share findings, ask questions, and learn from real experiences GHRP-2 is a synthetic growth hormone secretagogue that stimulates the pituitary gland to release growth hormone. It is one of the most potent members of the GHRP family, being 2-3 times more effective than GHRP-6 in stimulating GH release. Originally developed as a diagnostic agent for growth hormone deficiency, it works by mimicking ghrelin and binding to the GHS-R1a receptor. GHRP-2 acts as a synthetic agonist of ghrelin, binding to the growth hormone secretagogue receptor (GHS-R1a) in the hypothalamus and pituitary. This stimulates cAMP production and promotes pulsatile release of endogenous growth hormone without suppressing natural feedback loops. It works synergistically with GHRH to amplify GH secretion beyond what either peptide achieves alone.

First-line pharmacotherapy for ED of various etiologies including psychogenic, vasculogenic, and mixed. Effective in a broad range of patient populations including those with diabetes and post-prostatectomy. Daily low-dose tadalafil maintains steady plasma levels, allowing for spontaneous sexual activity without the need to time dosing around intercourse. FDA-approved at 5mg daily for treatment of BPH signs and symptoms, including urinary frequency, urgency, weak stream, and nocturia. Can be used alone or with alpha-blockers. Relaxes smooth muscle in the prostate, bladder neck, and urethra via PDE5 inhibition, improving urinary flow and reducing symptom severity. FDA-approved as Adcirca (40mg daily) for PAH (WHO Group 1) to improve exercise ability. Relaxes pulmonary vasculature and reduces right ventricular afterload. Enhances NO-cGMP signaling in systemic vasculature, improving flow-mediated dilation and arterial compliance. May slow progression of endothelial dysfunction. Modest systemic vasodilation produces small but clinically meaningful reductions in systolic and diastolic blood pressure, particularly in patients with mild hypertension. Enhanced NO-mediated vasodilation may increase blood flow to working muscles during resistance training, producing a more pronounced pump effect. Evidence is largely anecdotal but mechanistically plausible. Some evidence suggests PDE5 inhibition can improve exercise performance at altitude by reducing pulmonary artery pressure and improving oxygen delivery.